Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

This study is testing the immunotherapy drug tislelizumab in combination with other treatments for people with locally advanced non-small cell lung cancer that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with locally advanced non-small cell lung cancer (stage III) that cannot be surgically removed - You have not previously received chemotherapy or radiation for this cancer - Your cancer can be measured on imaging scans - You are in reasonably good overall health (able to carry out daily activities) **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body (stage IV) - You have a serious autoimmune disease - You have previously received immunotherapy - You have significant lung disease or have had major lung surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.